Articles found by an AI-assisted PubMed search that may be missing from CancerImmunoDB, shared so that curators and users can see what is being considered.
Why this exists: the database holds only about 10 articles a year for 2021–2024, and a plain PubMed search cannot judge whether a paper fits the scope.
| Year | Screened | Likely relevant |
|---|---|---|
| 2026 | 99 | 61 |
| 2025 | 100 | 81 |
| 2024 | 98 | 72 |
| 2023 | 92 | 45 |
| 2022 | 100 | 52 |
| 2021 | 85 | 49 |
360 articles shown. “In the database” counts the entries the database already has for each drug the AI named (cell line / animal / patient).
| PMID | Year | Article | Drugs | Study type | Cancer type | In the database | Curator status |
|---|---|---|---|---|---|---|---|
| 38429414 | 2024 | Modeling T cell temporal response to cancer immunotherapy rationalizes development of combinatorial treatment protocols. Nature cancer Likely relevant Tests anti-PD-1 therapy combined with anti-4-1BB agonist in vivo in mice and measures T cell dynamics and recruitment. | anti-programmed cell death protein 1 (PD-1); anti-4-1BB agonist | Animal | unspecified cancer | anti-programmed cell death protein 1 (PD-1) 0/0/0; anti-4-1BB agonist 0/0/0 | Awaiting curator check |
| 38489753 | 2024 | The Exonuclease TREX1 Constitutes an Innate Immune Checkpoint Limiting cGAS/STING-Mediated Antitumor Immunity. Cancer immunology research Likely relevant The study investigates genetic deficiency combined with T-cell-directed immune checkpoint blockade in vivo, measuring CD8+ T cells, NK cells, and myeloid compartment remodeling. | immune checkpoint blockade | Animal | tumor | immune checkpoint blockade 0/1/0 | Awaiting curator check |
| 38518770 | 2024 | CXCL9/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancer. Cell reports. Medicine Likely relevant Evaluates intratumoral vaccination with CXCL9/10-engineered dendritic cells combined with immune checkpoint blockade in murine NSCLC models and measures T cell infiltration and activation. | CXCL9/10-engineered dendritic cells; immune checkpoint blockade | Animal | Non-Small Cell Lung Cancer | CXCL9/10-engineered dendritic cells 0/0/0; immune checkpoint blockade 0/1/0 | Awaiting curator check |
| 38520088 | 2024 | EZH2 Inhibition Enhances PD-L1 Protein Stability Through USP22-Mediated Deubiquitination in Colorectal Cancer. Advanced science (Weinheim, Baden-Wurttemberg, Germany) Likely relevant Examines the effects of EZH2 inhibitors on PD-L1 stability and the tumor microenvironment in colorectal cancer cells. | EZH2 inhibitors; anti-PD-1 | Cell line | colorectal cancer | EZH2 inhibitors 0/0/0; anti-PD-1 14/36/0 | Awaiting curator check |
| 38550593 | 2024 | STING agonist inflames the cervical cancer immune microenvironment and overcomes anti-PD-1 therapy resistance. Frontiers in immunology Likely relevant The study experimentally tests the STING agonist MSA-2 alone and with anti-PD-1 in murine tumor models, assessing tumor microenvironment status and immune cell infiltration. | MSA-2; anti-PD-1 | Animal | cervical cancer | MSA-2 0/0/0; anti-PD-1 14/36/0 | Awaiting curator check |
| 38581017 | 2024 | Tumor microenvironment reprogramming combined with immunogenic enhancement by nanoemulsions potentiates immunotherapy. Journal of nanobiotechnology Likely relevant Tests melittin-encapsulated nanoemulsions combined with anti-CTLA-4 antibody in animal models, measuring cytotoxic T lymphocyte infiltration and antitumor T-cell responses. | anti-CTLA-4 antibody; melittin nanoemulsions | Animal | colorectal tumor | anti-CTLA-4 antibody 0/0/0; melittin nanoemulsions 0/0/0 | Awaiting curator check |
| 38588411 | 2024 | Ketogenic Diet Alters the Epigenetic and Immune Landscape of Prostate Cancer to Overcome Resistance to Immune Checkpoint Blockade Therapy. Cancer research Likely relevant Evaluates combinations of immune checkpoint blockade with HDAC inhibitors and dietary interventions in cell lines and animal models, measuring extensive immune landscape changes. | anti-PD1; anti-CTLA4; vorinostat | Mixed | prostate cancer | anti-PD1 1/1/0; anti-CTLA4 0/0/0; vorinostat 53/10/3 | Awaiting curator check |
| 38643157 | 2024 | Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation. Molecular cancer Likely relevant The study tests trametinib and PD-1/PD-L1 blockade in cancer cell lines and mouse models, measuring immune infiltrate, PD-L1 expression, and tumor microenvironment changes. | trametinib; PD-1/PD-L1 axis blockade | Mixed | KRAS-mutant lung adenocarcinoma | trametinib 59/33/6; PD-1/PD-L1 axis blockade 0/0/0 | Awaiting curator check |
| 38657120 | 2024 | IL1R2 Blockade Alleviates Immunosuppression and Potentiates Anti-PD-1 Efficacy in Triple-Negative Breast Cancer. Cancer research Likely relevant Tests IL1R2 blockade combined with anti-PD-1 in TNBC mouse models and measures TAMs, PD-L1, and exhausted CD8+ T cells. | IL1R2-neutralizing antibodies; anti-PD-1 | Animal | triple-negative breast cancer | IL1R2-neutralizing antibodies 0/0/0; anti-PD-1 14/36/0 | Awaiting curator check |
| 38697105 | 2024 | Next-generation anti-PD-L1/IL-15 immunocytokine elicits superior antitumor immunity in cold tumors with minimal toxicity. Cell reports. Medicine Likely relevant The study tests the immunocytokine LH05 and its combination with an oncolytic virus in animal tumor models, measuring immune cell infiltration and chemokines. | LH05; anti-PD-L1/interleukin-15 (IL-15) prodrug; oncolytic virus | Animal | advanced and metastatic tumors (cold tumors) | LH05 0/0/0; anti-PD-L1/interleukin-15 (IL-15) prodrug 0/0/0; oncolytic virus 0/0/0 | Awaiting curator check |
| 38703767 | 2024 | Assessing personalized responses to anti-PD-1 treatment using patient-derived lung tumor-on-chip. Cell reports. Medicine Likely relevant Primary research using a patient-derived lung tumor-on-chip platform to measure ex vivo effects of immune checkpoint inhibitors (anti-PD-1) on T cell-mediated cancer cell death. | anti-PD-1 | Mixed | non-small cell lung cancer | anti-PD-1 14/36/0 | Awaiting curator check |
| 38704109 | 2024 | Targeting tumorous Circ-E-Cadherinencoded C-E-Cad inhibits the recruitment and function of breast cancer-associated myeloid-derived suppressor cells. Pharmacological research Likely relevant The study tests anti-C-E-cad and anti-PD-1 antibodies in vivo and assesses their effect on MDSCs in breast cancer. | anti-C-E-cad; anti-PD-1 | Animal | breast cancer | anti-C-E-cad 0/0/0; anti-PD-1 14/36/0 | Awaiting curator check |
| 38711203 | 2024 | PI3K/mTOR inhibition induces tumour microenvironment remodelling and sensitises pS6high uterine leiomyosarcoma to PD-1 blockade. Clinical and translational medicine Likely relevant The study tests PI3K/mTOR inhibitors and anti-PD-1 blockade in patient-derived xenograft (PDX) models and measures their effects on immune infiltration, macrophage repolarization, and T-cell responses. | PI3K/mTOR inhibitors; anti-PD-1 | Animal | uterine leiomyosarcoma | PI3K/mTOR inhibitors 0/0/0; anti-PD-1 14/36/0 | Awaiting curator check |
| 38713626 | 2024 | Tumor-neutrophil cross talk orchestrates the tumor microenvironment to determine the bladder cancer progression. Proceedings of the National Academy of Sciences of the United States of America Likely relevant The study investigates targeting neutrophils or MET signaling combined with immune checkpoint blockade in mice, measuring changes in the immune microenvironment and CD8+ T cell response. | immune checkpoint blockade (ICB); MET signaling inhibitors | Animal | bladder cancer | immune checkpoint blockade (ICB) 0/0/0; MET signaling inhibitors 0/0/0 | Awaiting curator check |
| 38762492 | 2024 | Hsc70 promotes anti-tumor immunity by targeting PD-L1 for lysosomal degradation. Nature communications Likely relevant The study tests the Hsp90 inhibitor AUY-922 in mice and measures its effect on PD-L1 expression and anti-tumor immunity. | AUY-922; anti-PD-L1; anti-CTLA4 | Animal | unspecified | AUY-922 0/0/0; anti-PD-L1 0/15/0; anti-CTLA4 0/0/0 | Awaiting curator check |
| 38789460 | 2024 | Immune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer. Nature communications Likely relevant The study evaluates neoadjuvant chemo-immunotherapy (gemcitabine, cisplatin, and pembrolizumab) in bladder cancer patients and reports changes in immune gene signatures, plasma IL-9, and PD-L1/TIGIT expression. | gemcitabine; cisplatin; pembrolizumab | Patient | muscle-invasive bladder cancer | gemcitabine 30/23/10; cisplatin 18/3/11; pembrolizumab 0/0/16 | Awaiting curator check |
| 38805119 | 2024 | Janus kinase inhibitor overcomes resistance to immune checkpoint inhibitor treatment in peritoneal dissemination of gastric cancer in C57BL/6 J mice. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association Likely relevant Evaluates the combination of immune checkpoint inhibitors and a JAK inhibitor in a mouse tumor model and measures immune cell infiltration and phenotype. | anti-PD1; anti-CTLA4; Janus kinase inhibitor | Animal | gastric cancer | anti-PD1 1/1/0; anti-CTLA4 0/0/0; Janus kinase inhibitor 0/0/0 | Awaiting curator check |
| 38819989 | 2024 | Landscape of tumoral ecosystem for enhanced anti-PD-1 immunotherapy by gut Akkermansia muciniphila. Cell reports Likely relevant The study tests oral administration of Akkermansia muciniphila forms in combination with anti-PD-1 immunotherapy in mouse cancer models and measures various immune ecosystem changes. | anti-PD-1 | Animal | cancer | anti-PD-1 14/36/0 | Awaiting curator check |
| 38867043 | 2024 | Obesity induces PD-1 on macrophages to suppress anti-tumour immunity. Nature Likely relevant The study investigates the effect of anti-PD-1 blockade on tumour-associated macrophages and CD8+ T cells in animal models. | anti-PD-1; PD-1 blockade | Animal | cancer (general/unspecified tumour models) | anti-PD-1 14/36/0; PD-1 blockade 0/0/0 | Awaiting curator check |
| 38900577 | 2024 | TTK inhibitor OSU13 promotes immunotherapy responses by activating tumor STING. JCI insight Likely relevant The study investigates the TTK inhibitor OSU13 alone and combined with anti-PD-1 in cell lines, organoids, and mice, measuring STING activation and immune cell infiltration. | OSU13; anti-PD-1 | Mixed | melanoma, colon and breast cancer | OSU13 0/0/0; anti-PD-1 14/36/0 | Awaiting curator check |
| 38900864 | 2024 | JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma. Science (New York, N.Y.) Likely relevant The study tests ruxolitinib combined with nivolumab in a clinical trial and preclinical models, measuring changes in myeloid cells, neutrophil-to-lymphocyte ratios, and T cell function. | ruxolitinib; nivolumab | Mixed | Hodgkin lymphoma and solid tumors | ruxolitinib 1/0/0; nivolumab 1/2/4 | Awaiting curator check |
| 38916448 | 2024 | Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma. Cancer research communications Likely relevant Tests amivantamab and pembrolizumab in PDX models and measures changes in tumor-infiltrating T cells and metabolic markers associated with immunosuppression. | amivantamab; pembrolizumab | Animal | head and neck squamous cell carcinoma and lung squamous cell carcinoma | amivantamab 0/0/0; pembrolizumab 0/0/16 | Awaiting curator check |
| 38957477 | 2024 | Faecalibaterium prausnitzii strain EXL01 boosts efficacy of immune checkpoint inhibitors. Oncoimmunology Likely relevant Tests the administration of Faecalibacterium prausnitzii strain EXL01 in tumor-bearing mice and in vitro to evaluate its effects on T cell activation and anti-tumor responses to immune checkpoint inhibitors. | Faecalibacterium prausnitzii strain EXL01; immune checkpoint inhibitors | Animal | Non-Small Cell Lung Cancer and Advanced Melanoma | Faecalibacterium prausnitzii strain EXL01 0/0/0; immune checkpoint inhibitors 0/0/0 | Awaiting curator check |
| 38973593 | 2024 | DHODH inhibition enhances the efficacy of immune checkpoint blockade by increasing cancer cell antigen presentation. eLife Likely relevant Tests the DHODH inhibitor brequinar and immune checkpoint blockers in a mouse melanoma model, measuring antigen presentation and MHC class I. | brequinar; anti-CTLA-4; anti-PD-1 | Animal | melanoma | brequinar 0/0/0; anti-CTLA-4 1/10/7; anti-PD-1 14/36/0 | Awaiting curator check |
| 39002018 | 2024 | Targeting CD73 limits tumor progression and enhances anti-tumor activity of anti-PD-1 therapy in intrahepatic cholangiocarcinoma. Journal of cancer research and clinical oncology Likely relevant The study tests the CD73 enzymatic inhibitor AB680 combined with PD-1 blockade or chemotherapy in murine models, measuring changes in tumor-infiltrating immune cell populations and activation markers like Granzyme B and Tbet. | AB680; PD-1 antibody; gemcitabine; cisplatin | Animal | intrahepatic cholangiocarcinoma | AB680 0/0/0; PD-1 antibody 0/3/0; gemcitabine 30/23/10; cisplatin 18/3/11 | Awaiting curator check |